Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Summary

This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

Timeline

Start

2009-01

Primary completion

2013-04

Completion

2013-10

Drugs

Indications